A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. - Wikidata - awgldk - TriplyDB

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.

http://www.wikidata.org/entity/Q39991720

about

The MET axis as a therapeutic target.MET inhibitors in combination with other therapies in non-small cell lung cancer The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents Efficacy of c-Met inhibitor for advanced prostate cancer.Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice.Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells.TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer MET targeted therapy for lung cancer: clinical development and future directions Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer?Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.Molecular changes in smoking-related lung cancer.Molecular determinants of lung cancer metastasis to the central nervous system.KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis.Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma.Drug efficacy testing in mice.Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases.Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis.MET expression in melanoma correlates with a lymphangiogenic phenotype.Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions.Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer.A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models.FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.

P2860

Q24609682-EB99B701-A113-4AB6-96BE-EAB0911C4138 Q26823203-4778F173-A3CE-435E-A810-C1FBA3207FC1 Q26823903-A4702A21-092A-436F-9361-1B50D6A2F657 Q33718726-98B94C13-CDA1-400E-863A-34F81688C7F2 Q34348237-25697F5B-D3F8-45EC-BC84-9C7F67EC9389 Q34429001-1BFA4648-8FCB-44C0-BAC6-6FCC4C9B81E1 Q35006543-220A9A85-E4BF-46AA-BDFC-3EF578E4F9D9 Q35370365-B81E38AA-DAA8-4B15-AE74-1129AA28BCF2 Q37645240-4C2E9A07-EAF6-471B-B9E5-B683EB4DA75D Q37697193-4B891E3F-B797-4F31-BD0B-73728491F717 Q37730020-C6124D9F-5488-4F8E-BD2C-7F9EAFF0F74C Q37963519-7C580AB2-514F-49C3-BBD8-DEE5FB3B3E56 Q38390049-1DAF373A-EB9A-4F57-81C9-089D2AEFE1F1 Q38669282-15EE0D2E-1F2E-44EC-AAC5-33B0C9BCA33E Q39007909-EDBB2595-2799-468B-B100-A455E1D55D48 Q39328954-935CF5FA-120A-4074-A420-F0A034E9B308 Q39493552-D3BB3E33-D290-4265-82D8-4EC97BD4244E Q39604398-534708FF-5320-41B8-969A-58C256C6004E Q39739616-DED74C35-57DB-4892-8D83-D741795B9133 Q41626594-C79E6876-05E7-4B0F-92B4-5345257A89DF Q42819406-4F5A5FA9-ABBC-4E64-86CE-BDA2758BD770 Q44841828-5824F0E6-0B14-48FA-8BE6-C0DEB3904723 Q47160963-12018D79-7D20-422A-9F9A-1257DF810177 Q51110603-ED8C129D-4F87-4527-933A-901B4ED225DE Q53058993-32A7EBA2-0AC4-4C70-9797-DA8A3E73432C

P2860

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.

http://www.wikidata.org/entity/Q39991720

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

A selective small molecule inh ...... nancy induced by mutant K-ras.

@en

A selective small molecule inh ...... nancy induced by mutant K-ras.

@nl

type

label

A selective small molecule inh ...... nancy induced by mutant K-ras.

@en

A selective small molecule inh ...... nancy induced by mutant K-ras.

@nl

prefLabel

A selective small molecule inh ...... nancy induced by mutant K-ras.

@en

A selective small molecule inh ...... nancy induced by mutant K-ras.

@nl

P1433

Q39991720-D2E07193-9FF3-4BA5-84F2-1BEC015541EF

P1476

Q39991720-3136BD7C-92F7-4491-B32A-1964CE850237

P2093

Q39991720-14112A22-C852-4856-98F2-7EB0893C1323

Q39991720-41A0A7D2-728D-4168-BF3C-22CC956E84D8

Q39991720-70C99E85-8FB9-4006-A32E-059A7D043C5D

Q39991720-7797E5E7-E336-46CD-8843-EDD01920E1C6

Q39991720-7B914903-8D7B-4F2C-B8FC-3EF5C14BF0CC

Q39991720-7C91B8EE-8A9A-4913-923B-EBE6FC7E6307

Q39991720-807D5FF1-A954-4A78-BBEA-88AE70FB6BDC

Q39991720-D36A451B-0A89-4FED-AC6D-364DCD45A203

Q39991720-D9FC8D55-AB53-4428-B1B7-6AD768AB0199

Q39991720-F23728E2-8443-4C1A-B34A-693104A2DCE0

P2860

Q39991720-07DE2095-4D6D-4902-B68A-87236447E31D

Q39991720-12B863BE-D595-44DE-9A92-F8C5020B9D08

Q39991720-1EEB2607-4420-43B5-883E-8E99FD08C564

Q39991720-29E25444-75A2-4DC0-8AA3-2F0B1445275E

Q39991720-2FED5FB7-6CFE-4AF8-BA8A-B572C5173C27

Q39991720-5A089461-387B-47B1-9F91-DFFE1B72443D

Q39991720-866D4BA5-B716-4543-88D3-D4A9EFB3F7D9

Q39991720-92056126-24AD-433C-AB4B-7A9C6E51D63D

Q39991720-9C0A450B-D232-4833-AFEA-3142A6A24C9F

Q39991720-9FB620C1-86C6-42C4-B402-8E345CA6B732

P304

Q39991720-267A2434-E010-47E4-9F9C-EE361CF309EE

P31

Q39991720-58F6BEDC-BFCF-4975-AF11-07DEBFEB88F4

P356

Q39991720-8E1DFF34-8585-4086-B2CA-8221660A9F6A

P433

Q39991720-293391B2-97F8-4BA0-901E-53DF8852A90C

P478

Q39991720-F8550F0A-DC64-4AAD-B26A-5FE2DBDEA2DF

P50

Q39991720-475E5DDE-7C12-4987-9EEC-05431466B9EC

P577

Q39991720-71D56A9A-0329-400D-B185-F323FA69159E

P698

Q39991720-E612F7A6-034C-49BC-A77D-2389FEB32588

P921

Q39991720-F2F894A4-CAF6-4A48-8B06-DB93424A807A

P932

Q39991720-B146D7FC-38E8-4838-8365-A53D8A8EDE93

P356

1535-7163.MCT-07-2045

P1433

Molecular Cancer Therapeutics

P1476

A selective small molecule inh ...... nancy induced by mutant K-ras.

@en

P2093

Amy E Hanna

http://www.w3.org/2001/XMLSchema#string

Diane Liu

http://www.w3.org/2001/XMLSchema#string

Faye M Johnson

http://www.w3.org/2001/XMLSchema#string

Futoshi Uno

http://www.w3.org/2001/XMLSchema#string

Jonathan M Kurie

http://www.w3.org/2001/XMLSchema#string

Julie G Izzo

http://www.w3.org/2001/XMLSchema#string

Lin Ji

http://www.w3.org/2001/XMLSchema#string

Ludmila Prudkin

http://www.w3.org/2001/XMLSchema#string

Marie Wislez

http://www.w3.org/2001/XMLSchema#string

Nobukazu Fujimoto

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo

c-Met: structure, functions and potential for therapeutic inhibition

c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma

High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras

Cancer statistics, 2006

K-ras mutations in non-small-cell lung carcinoma: a review.

Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

P304

952-960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-07-2045

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Ignacio I Wistuba

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18413809

http://www.w3.org/2001/XMLSchema#string

P921

P932

3378059

http://www.w3.org/2001/XMLSchema#string